Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-450/r/ABT-267 + ABT-333 with ribavirin for hepatitis C genotype 1 with compensated cirrhosis
2012-003088-23Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ombitasvir + paritaprevir + ritonavir, dasabuvir and ribavirin in hepatitis C virus infection and Cirrhosis (2 arms), sponsored by AbbVie Inc. Primary endpoints: SVR12 rate and Safety. Started Oct 2012; status: completed.
02
Drugs
ombitasvir + paritaprevir + ritonavirdasabuvirribavirin
03
Conditions
hepatitis C virus infectionCirrhosis
Beyond the preview
Go deeper on 2012-003088-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003088-23.